Key Points
- Insider sale: Derek Maetzold sold 1,339 shares on Jan. 6 at an average of $40.10 for about $53,694, trimming his stake by 4.34% to 29,513 shares (≈$1.18M).
- Stock and recent results: CSTL trades near $40.61 with a $1.19B market cap and a 52‑week range of $14.59–$42.17, and the company posted an EPS of ($0.02) and revenue of $80.55M last quarter, both beating expectations.
- Analyst and institutional backdrop: Six analysts rate the stock Buy (overall "Moderate Buy" consensus, $43.17 average target), while institutional investors own ~92.6% of the shares and several large funds recently increased positions.
Castle Biosciences, Inc. (NASDAQ:CSTL - Get Free Report) insider Derek Maetzold sold 1,339 shares of the business's stock in a transaction on Tuesday, January 6th. The stock was sold at an average price of $40.10, for a total value of $53,693.90. Following the sale, the insider owned 29,513 shares in the company, valued at approximately $1,183,471.30. The trade was a 4.34% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link.
Castle Biosciences Trading Up 1.3%
Shares of CSTL stock opened at $40.61 on Thursday. The stock has a market cap of $1.19 billion, a P/E ratio of -90.24 and a beta of 1.06. The company has a quick ratio of 6.31, a current ratio of 6.47 and a debt-to-equity ratio of 0.02. Castle Biosciences, Inc. has a fifty-two week low of $14.59 and a fifty-two week high of $42.17. The business has a fifty day simple moving average of $37.07 and a 200-day simple moving average of $26.60.
Castle Biosciences (NASDAQ:CSTL - Get Free Report) last issued its quarterly earnings data on Monday, November 3rd. The company reported ($0.02) EPS for the quarter, beating analysts' consensus estimates of ($0.34) by $0.32. Castle Biosciences had a negative net margin of 3.56% and a positive return on equity of 1.73%. The firm had revenue of $80.55 million for the quarter, compared to analysts' expectations of $71.06 million. On average, analysts forecast that Castle Biosciences, Inc. will post 0.44 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Large investors have recently modified their holdings of the stock. Portolan Capital Management LLC grew its holdings in Castle Biosciences by 1.7% in the third quarter. Portolan Capital Management LLC now owns 1,515,111 shares of the company's stock valued at $34,499,000 after purchasing an additional 25,539 shares during the period. Dimensional Fund Advisors LP boosted its holdings in shares of Castle Biosciences by 7.0% in the 3rd quarter. Dimensional Fund Advisors LP now owns 1,474,089 shares of the company's stock valued at $33,564,000 after purchasing an additional 96,084 shares during the last quarter. Wasatch Advisors LP grew its stake in shares of Castle Biosciences by 5.1% during the 2nd quarter. Wasatch Advisors LP now owns 1,049,773 shares of the company's stock valued at $21,436,000 after buying an additional 51,318 shares during the period. Braidwell LP increased its holdings in shares of Castle Biosciences by 125.3% during the 2nd quarter. Braidwell LP now owns 822,735 shares of the company's stock worth $16,800,000 after buying an additional 457,488 shares during the last quarter. Finally, Allianz Asset Management GmbH raised its position in shares of Castle Biosciences by 11.6% in the 2nd quarter. Allianz Asset Management GmbH now owns 713,742 shares of the company's stock worth $14,575,000 after buying an additional 74,265 shares during the period. 92.60% of the stock is currently owned by hedge funds and other institutional investors.
Analyst Ratings Changes
CSTL has been the topic of a number of analyst reports. Weiss Ratings reiterated a "sell (d)" rating on shares of Castle Biosciences in a report on Monday, December 29th. BTIG Research lifted their price objective on Castle Biosciences from $38.00 to $50.00 and gave the stock a "buy" rating in a research report on Friday, December 12th. Zacks Research cut shares of Castle Biosciences from a "strong-buy" rating to a "hold" rating in a research note on Friday, January 2nd. Guggenheim lifted their price target on shares of Castle Biosciences from $30.00 to $43.00 and gave the stock a "buy" rating in a report on Monday. Finally, Canaccord Genuity Group upped their price objective on shares of Castle Biosciences from $37.00 to $50.00 and gave the company a "buy" rating in a research note on Monday, December 22nd. Six investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Castle Biosciences presently has an average rating of "Moderate Buy" and an average price target of $43.17.
Get Our Latest Report on CSTL
Castle Biosciences Company Profile
(
Get Free Report)
Castle Biosciences, Inc is a molecular diagnostics company specializing in the development and commercialization of prognostic and diagnostic tests for patients with dermatologic conditions. The company's proprietary portfolio of genomic assays is designed to improve risk assessment and guide clinical decision-making for individuals with skin cancers and other skin-related diseases. By combining genomic data with advanced statistical algorithms, Castle Biosciences seeks to provide actionable insights that help physicians tailor treatment plans and monitoring strategies.
The company's flagship test, DecisionDx-Melanoma, evaluates the probability of metastasis in patients diagnosed with cutaneous melanoma, supporting more personalized surveillance and therapeutic approaches.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
